Gene: HLA-G

3135
MHC-G
major histocompatibility complex, class I, G
protein-coding
6p22.1
Ensembl:ENSG00000204632 MIM:142871 Vega:OTTHUMG00000031157 UniprotKB:P17693
NG_029039.1
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
NA (AD)  NA (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg21727129chr6:29793709HLA-GPromoter1.138e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MX20.689
SLC15A30.682
HLA-F0.678
SP1000.677
HLA-B0.675
CYTIP0.673
EPSTI10.669
ODF3B0.66
IFITM10.66
LGALS90.655

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ZNF835-0.346
FRMPD1-0.342
MYADML2-0.326
FUT9-0.313
CYP46A1-0.311
HNF1A-0.301
NEUROD6-0.301
TMEM221-0.299
THNSL1-0.298
ST6GAL2-0.296

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5301712,2,2,-trichloro-1-(3,4-dichlorophenyl)-ethylacetate"2,2,2,-trichloro-1-(3,4-dichlorophenyl)-ethylacetate results in increased expression of HLA-G mRNA"22119440
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-G mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-G mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-G mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-G mRNA"27188386
D000806Angiotensin-Converting Enzyme InhibitorsAngiotensin-Converting Enzyme Inhibitors affects the expression of HLA-G mRNA25811541
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of HLA-G mRNA24449571
C006632arsenic trioxidearsenic trioxide results in decreased expression of HLA-G mRNA15725085|1576101
D001241AspirinAspirin results in decreased expression of HLA-G mRNA14976132
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of HLA-G mRNA"19150397
D004958Estradiol[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of HLA-G mRNA19619570
D004958EstradiolEstradiol results in increased expression of HLA-G mRNA19619570|2118537
C099952bifenthrinbifenthrin results in increased expression of HLA-G mRNA24938463
C099952bifenthrinfulvestrant inhibits the reaction [bifenthrin results in increased expression of HLA-G mRNA]24938463
C006780bisphenol Abisphenol A results in increased expression of HLA-G mRNA25181051
D002034BumetanideBumetanide affects the expression of HLA-G mRNA25811541
D002220CarbamazepineCarbamazepine affects the expression of HLA-G mRNA25811541
D002434CefadroxilCefadroxil affects the expression of HLA-G mRNA25811541
D002437CefazolinCefazolin affects the expression of HLA-G mRNA25811541
D002939CiprofloxacinCiprofloxacin affects the expression of HLA-G mRNA25811541
C018021cobaltous chloridecobaltous chloride results in increased expression of HLA-G mRNA19376846
D016572CyclosporineCyclosporine results in increased expression of HLA-G mRNA22147139
C014347decitabine[decitabine affects the methylation of HLA-G promoter] which affects the expression of HLA-G mRNA18498645|1849864
C014347decitabine[decitabine affects the methylation of HLA-G promoter] which affects the expression of HLA-G protein18823661|1882366
C014347decitabinedecitabine results in increased expression of HLA-G mRNA17949227
C014347decitabinedecitabine results in increased expression of HLA-G protein17949227
D002945CisplatinHLA-G protein affects the susceptibility to Cisplatin16217747
D002945Cisplatin[Piroxicam co-treated with Cisplatin] results in increased expression of HLA-G mRNA21858171
C118739entinostatentinostat results in increased expression of HLA-G mRNA27188386
D004785Environmental PollutantsEnvironmental Pollutants affects the expression of HLA-G mRNA19118595
D004917ErythromycinErythromycin affects the expression of HLA-G mRNA25811541
D005472FluorouracilFluorouracil results in increased expression of HLA-G mRNA16101138
C070081fulvestrantfulvestrant inhibits the reaction [bifenthrin results in increased expression of HLA-G mRNA]24938463
C057619glimepirideglimepiride affects the expression of HLA-G mRNA25811541
D007069IfosfamideIfosfamide affects the expression of HLA-G mRNA25811541
D020910KetorolacKetorolac affects the expression of HLA-G mRNA25811541
D017706LisinoprilLisinopril affects the expression of HLA-G mRNA25811541
C059500meropenemmeropenem affects the expression of HLA-G mRNA25811541
D008727MethotrexateHLA-G gene polymorphism affects the susceptibility to Methotrexate16906016
D008727MethotrexateMethotrexate results in decreased expression of HLA-G mRNA17400583
D008727MethotrexateMethotrexate results in increased expression of HLA-G protein modified form16906016
D015735MifepristoneMifepristone inhibits the reaction [Progesterone results in increased expression of HLA-G mRNA]16210391|2249065
D015735MifepristoneMifepristone inhibits the reaction [Progesterone results in increased expression of HLA-G protein]16210391
C512715NSC-87877NSC-87877 inhibits the reaction [[HLA-G protein results in increased phosphorylation of and results in increased activity of PTPN11 protein] which results in decreased phosphorylation of and results in decreased activity of MTOR protein]21887223
C512715NSC-87877NSC-87877 inhibits the reaction [PTPN11 protein results in increased activity of HLA-G protein]21887223
D009853OmeprazoleOmeprazole affects the expression of HLA-G mRNA25811541
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-G mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of HLA-G mRNA26272509
D010894Piroxicam[Piroxicam co-treated with Cisplatin] results in increased expression of HLA-G mRNA21858171
D011374ProgesteroneMifepristone inhibits the reaction [Progesterone results in increased expression of HLA-G mRNA]16210391|2249065
D011374ProgesteroneMifepristone inhibits the reaction [Progesterone results in increased expression of HLA-G protein]16210391
D011374ProgesteroneProgesterone results in increased expression of HLA-G mRNA16210391|2249065
D011374ProgesteroneProgesterone results in increased expression of HLA-G protein16210391|1952722
D011739PyrimethaminePyrimethamine affects the expression of HLA-G mRNA25811541
D015474IsotretinoinIsotretinoin results in increased expression of HLA-G mRNA20436886
D012293RifampinRifampin affects the expression of HLA-G mRNA25811541
D012643SeleniumSelenium results in increased expression of HLA-G mRNA19244175
D012972Sodium HydroxideHLA-G SNP affects the susceptibility to Sodium Hydroxide27258892
D018038Sodium SeleniteSodium Selenite results in increased expression of HLA-G mRNA18175754
D013420SulfamethoxazoleSulfamethoxazole affects the expression of HLA-G mRNA25811541
C061133tamibarotenetamibarotene results in increased expression of HLA-G mRNA15498508
D013749Tetrachlorodibenzodioxin[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of HLA-G mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of HLA-G mRNA22574217
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of HLA-G mRNA19619570
D014212TretinoinTretinoin results in increased expression of HLA-G mRNA15498508|1589460
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-G mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of HLA-G mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of HLA-G mRNA19101580|2317975
D014810Vitamin EVitamin E results in increased expression of HLA-G mRNA19244175
C111237vorinostatvorinostat results in increased expression of HLA-G mRNA27188386
D015032ZincZinc deficiency results in increased expression of HLA-G mRNA18356318

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005102signaling receptor binding-IBA21873635  
GO:0005102signaling receptor binding-IPI20702625  22802125  
GO:0005515protein binding-IPI16455647  17056715  19583775  24899623  
GO:0042605peptide antigen binding-IBA21873635  
GO:0042802identical protein binding-IPI16455647  18550825  
GO:0042803protein homodimerization activity-IDA22802125  
GO:0042803protein homodimerization activity-NAS18550825  
GO ID GO Term Qualifier Evidence PubMed
GO:0001916positive regulation of T cell mediated cytotoxicity-IBA21873635  
GO:0002474antigen processing and presentation of peptide antigen via MHC class I-IBA21873635  
GO:0002474antigen processing and presentation of peptide antigen via MHC class I-TAS-  
GO:0002476antigen processing and presentation of endogenous peptide antigen via MHC class Ib-IBA21873635  
GO:0002479antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent-TAS-  
GO:0002480antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent-TAS-  
GO:0002645positive regulation of tolerance induction-IMP22802125  
GO:0002666positive regulation of T cell tolerance induction-IMP20448110  
GO:0002767immune response-inhibiting cell surface receptor signaling pathway-IDA20702625  
GO:0006955immune response-IBA21873635  
GO:0006968cellular defense response-TAS9539768  
GO:0032735positive regulation of interleukin-12 production-IDA20702625  
GO:0042130negative regulation of T cell proliferation-IDA20702625  
GO:0045591positive regulation of regulatory T cell differentiation-IMP20448110  
GO:0050776regulation of immune response-TAS-  
GO:0050777negative regulation of immune response-IC22802125  
GO:0060333interferon-gamma-mediated signaling pathway-TAS-  
GO:0060337type I interferon signaling pathway-TAS-  
GO:2001199negative regulation of dendritic cell differentiation-IDA20702625  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-TAS-  
GO:0005576extracellular region-IEA-  
GO:0005886plasma membrane-IBA21873635  
GO:0005886plasma membrane-TAS-  
GO:0012507ER to Golgi transport vesicle membrane-TAS-  
GO:0016020membrane-HDA19946888  
GO:0030670phagocytic vesicle membrane-TAS-  
GO:0031901early endosome membrane-TAS-  
GO:0042612MHC class I protein complex-IEA-  
GO:0055038recycling endosome membrane-TAS-  
GO:0071556integral component of lumenal side of endoplasmic reticulum membrane-TAS-  
KEGG ID KEGG Term
hsa04144Endocytosis
hsa04145Phagosome
hsa04514Cell adhesion molecules (CAMs)
hsa04612Antigen processing and presentation
hsa04650Natural killer cell mediated cytotoxicity
hsa04940Type I diabetes mellitus
hsa05320Autoimmune thyroid disease
hsa05330Allograft rejection
hsa05332Graft-versus-host disease
hsa05416Viral myocarditis
Reactome ID Reactome Term Evidence
R-HSA-1236974ER-Phagosome pathwayTAS
R-HSA-1236974ER-Phagosome pathwayIEA
R-HSA-1236975Antigen processing-Cross presentationTAS
R-HSA-1236975Antigen processing-Cross presentationIEA
R-HSA-1236977Endosomal/Vacuolar pathwayTAS
R-HSA-1280215Cytokine Signaling in Immune systemTAS
R-HSA-1280218Adaptive Immune SystemIEA
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-168256Immune SystemIEA
R-HSA-198933Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cellTAS
R-HSA-877300Interferon gamma signalingTAS
R-HSA-909733Interferon alpha/beta signalingTAS
R-HSA-913531Interferon SignalingTAS
R-HSA-983169Class I MHC mediated antigen processing & presentationIEA
R-HSA-983169Class I MHC mediated antigen processing & presentationTAS
R-HSA-983170Antigen Presentation: Folding, assembly and peptide loading of class I MHCIEA
R-HSA-983170Antigen Presentation: Folding, assembly and peptide loading of class I MHCTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
18721275HLA-G polymorphism and transitional cell carcinoma of the bladder in a Brazilian population. (2008 Aug)Castelli ECTissue Antigens
27004472Soluble Human Leukocyte Antigen-G in the Bronchoalveolar Lavage of Lung Cancer Patients. (2016 Aug)Montilla DArch Bronconeumol